CE MARKING OF THE FIRST BLOOD TEST FOR EARLY ALZHEIMER’S DIAGNOSIS

DiaGenic ASA today announces the European release of its ADtec® (Alzheimer’s) blood-based gene-expression assay for clinical diagnostic use. The Alzheimer’s assay is released as a CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices 98/79/EC. ADtect® gene expression test employs an easy to collect blood sample and offers hope for early intervention and treatment. “This CE marking is a major milestone in DiaGenic’s development and constitutes a breakthrough in the diagnosis and therapy of Alzheimer’s disease,” says DiaGenic CEO Erik Christensen, MD, PhD. “Current evidence suggests that pharmacological treatments and caregiver interventions can delay entry into nursing homes and thus reducing healthcare costs. However, these cost savings are not being realized because many patients with AD are either not diagnosed or diagnosed at a late stage of the disease. We envisage ADtect® with its rapid and convenient sample collection playing a front line role.” ADtectTM will be marketed through a network of distributors in Europe with test analysis performed centrally by DNAVision in Belgium. Contact: MD PhD Erik Christensen, Managing Director Telephone: +47 95939918 e-mail: erik.christensen@diagenic.com